{"id":728227,"date":"2023-02-02T08:53:10","date_gmt":"2023-02-02T13:53:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/"},"modified":"2023-02-02T08:53:10","modified_gmt":"2023-02-02T13:53:10","slug":"silo-pharma-announces-expansion-of-intellectual-property-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/","title":{"rendered":"Silo Pharma Announces Expansion of Intellectual Property Portfolio"},"content":{"rendered":"

\nSilo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders
\n<\/h2>\n
\n

ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc.<\/u><\/b><\/a>(Nasdaq: SILO) (\u201cthe Company\u201d),<\/b> a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled \u201cPharmacological Prophylactics Against Stress-Induced Affective Disorders In Females.\u201d The allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder (PTSD).<\/p>\n

\u201cAfter a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD, and related disorders,\u201d said Eric Weisblum, Chief Executive Officer<\/p>\n

Through its commercial evaluation license agreement with Columbia University, the Company holds an option to license certain assets currently under development by Columbia, including potential treatments for stress-induced affective disorders and Alzheimer\u2019s disease.<\/p>\n

SPC-15 is a targeted prophylactic using ketamine compositions as a method of treatment and prevention for stress-induced affective disorders including PTSD. The treatment predicts levels of severity or progression of such disorders and their metabolomic biomarkers\u2019 response to pharmacological treatments.<\/p>\n

With the patent announced today, the Company expands its intellectual property and technology rights for the treatment of rare diseases,<\/p>\n

\n About Silo Pharma<\/b>
\n
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer\u2019s disease, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit\u00a0www.silopharma.com<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/b>
\n
All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is\/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.<\/p>\n

\n Contact\u00a0<\/b>
\n
800-705-0120
investors@silopharma.com<\/u><\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc.(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled \u201cPharmacological Prophylactics Against Stress-Induced Affective Disorders In Females.\u201d The allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder (PTSD). \u201cAfter a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its … <\/p>\n

Continue reading “Silo Pharma Announces Expansion of Intellectual Property Portfolio”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728227","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilo Pharma Announces Expansion of Intellectual Property Portfolio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Announces Expansion of Intellectual Property Portfolio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc.(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled \u201cPharmacological Prophylactics Against Stress-Induced Affective Disorders In Females.\u201d The allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder (PTSD). \u201cAfter a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its … Continue reading "Silo Pharma Announces Expansion of Intellectual Property Portfolio"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-02T13:53:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Announces Expansion of Intellectual Property Portfolio\",\"datePublished\":\"2023-02-02T13:53:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/\"},\"wordCount\":489,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/\",\"name\":\"Silo Pharma Announces Expansion of Intellectual Property Portfolio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==\",\"datePublished\":\"2023-02-02T13:53:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Announces Expansion of Intellectual Property Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Announces Expansion of Intellectual Property Portfolio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Announces Expansion of Intellectual Property Portfolio - Market Newsdesk","og_description":"Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc.(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled \u201cPharmacological Prophylactics Against Stress-Induced Affective Disorders In Females.\u201d The allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder (PTSD). \u201cAfter a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its … Continue reading \"Silo Pharma Announces Expansion of Intellectual Property Portfolio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-02T13:53:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Announces Expansion of Intellectual Property Portfolio","datePublished":"2023-02-02T13:53:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/"},"wordCount":489,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/","name":"Silo Pharma Announces Expansion of Intellectual Property Portfolio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==","datePublished":"2023-02-02T13:53:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTY1MyM1Mzg4NjU4IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-expansion-of-intellectual-property-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Announces Expansion of Intellectual Property Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728227"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}